ATB0, +-targeted delivery of triptolide prodrugs for safer and more effective pancreatic cancer therapy. (1st February 2021)

• Record Type: Journal Article
• Authors: Lou, Dan; Lou, Zijian; Lin, Yuanzhen; Shangguan, Hao; Lin, Yujie; Luo, Qiuhua; Zhang, Hailin; Lin, Guangyong; Chen, Ruijie; Kou, Longfa; Bao, Shihui
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 33(2021)
• Publication Date: 2021-02-01
• Subjects: Triptolide -- ATB0, + -- rodrug -- Amino acid conjugate -- Pancreatic cancer; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2020.127728
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Abstract: Triptolide (TP) is a diterpene epoxide component extracted from Tripterygium wilfordii and has been shown to possess an impressive anticancer effect. However, TP has not yet entered any clinic trials due to the severe adverse effects that resulted from the off-target absorption and distribution found in animal studies. In this study, we designed and synthesized three amino acids (tryptophan, valine, and lysine) based TP prodrugs to target ATB 0, + which are highly expressed in pancreatic cancer cells for more effective pancreatic cancer therapy. The stability, uptake profiles, uptake mechanism, and cancer-killing ability were studied in vitro. All three prodrugs showed increased uptake and enhanced cytotoxicity in pancreatic cancer cells, but not in normal pancreatic cells. The difference in killing effect on normal and cancer cells was attributed to pancreatic cancer over-expressed ATB 0, + -mediated uptake. Specifically, tryptophan-conjugated TP prodrug (TP-Trp) showed the highest uptake and the best cancer cell killing effect, considered as the best candidate. The present study provided the proof-of-concept of exploiting TP prodrug to target ATB 0, + for pancreatic cancer-selective delivery and treatment.